Revlimid — Medica
Small Lymphocytic Leukemia
Initial criteria
- age ≥ 18 years
- relapsed or refractory disease
- patient has tried at least one Bruton-tyrosine kinase inhibitor (examples: ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib)
- patient has tried at least one B-cell lymphoma (BCL2) inhibitor (example: venetoclax)
Approval duration
1 year